Respiration最新文献

{"title":"Asthma phenotype can be influenced by recurrent respiratory infections in patients with primary antibody deficiency: the impact of Ig therapy.","authors":"Emanuele Vivarelli, Margherita Perlato, Matteo Accinno, Barbara Brugnoli, Maria Elena Milanese, Edoardo Cataudella, Giuseppe Licci, Giandomenico Maggiore, Oliviero Rossi, Paola Parronchi, Lorenzo Cosmi, Alessandra Vultaggio, Andrea Matucci","doi":"10.1159/000543792","DOIUrl":"https://doi.org/10.1159/000543792","url":null,"abstract":"<p><strong>Introduction: </strong>Asthma is a heterogeneous chronic inflammatory disease involving different underling pathogenetic mechanisms. We aimed to investigate the characteristics of patients with the diagnosis of asthma and primary antibody immunodeficiency (PAD) and the impact of immunoglobulin therapy (IVIg) Methods: Thirty-three patients with severe asthma and PAD (either IgG subclasses deficiency or unclassified hypogammaglobulinemia) were retrospectively recruited. Severe asthma was diagnosed according to GINA recommendations and PAD was diagnosed according to ESID diagnostic criteria; normal immunoglobulins serum levels were defined according to the local laboratory values (IgG 700-1600 mg/dl; IgA 70-400 mg/dl; IgM 40-230 mg/dl; IgG1 382-929 mg/dl; IgG2 242-700 mg/dl; IgG3 22-176 mg/dl; IgG4 4-88 mg/dl). Clinical and laboratory features were analyzed before and after immunoglobulin therapy (IVIg).</p><p><strong>Results: </strong>We observed a high proportion of patients with low T2 markers (36.4%), including low blood eosinophils (BE), compared to patients with elevated T2 markers (BE: 80 (range 30-140) vs 200 (range 50-760) cells/microL, p<0.001). After IVIg, we observed significant reduction of respiratory infections (4 (range 0-20) vs 1 (range 0-5), p<0.001) and exacerbations (6 (range 1-20) vs 1 (range 0-7); p<0.001); moreover, in patients with low T2 markers, BE significantly rose (80 (range 30-140) vs 115 (range 70-520) cells/microL, p<0.05).</p><p><strong>Conclusion: </strong>IVIg therapy reduces infections and infection-related exacerbations in patients with the diagnosis of asthma and PAD, and could modulate asthma phenotype.</p>","PeriodicalId":21048,"journal":{"name":"Respiration","volume":" ","pages":"1-15"},"PeriodicalIF":3.5,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143597533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaccination strategies in respiratory diseases: recommendation from AIPO-ITS/ETS, SIMIT, SIP/IRS and SItI.","authors":"Claudio Micheletto, Stefano Aliberti, Massimo Andreoni, Francesco Blasi, Fabiano Di Marco, Rosa Di Matteo, Giovanni Gabutti, Sergio Harari, Ivan Gentile, Roberto Parrella, Roberta Siliquini, Laura Sticchi","doi":"10.1159/000544919","DOIUrl":"https://doi.org/10.1159/000544919","url":null,"abstract":"<p><p>Chronic respiratory diseases, including asthma, chronic obstructive pulmonary disease, and bronchiectasis, are significant global health concerns associated with recurrent exacerbations, hospitalization, and increased mortality. Preventive strategies, particularly vaccination, play a crucial role in managing these diseases by reducing infection-related exacerbations and stabilizing lung function. This review summarizes the recommendations provided by four major Italian scientific societies on vaccination against key respiratory pathogens, including respiratory syncytial virus, influenza, SARS-CoV-2, Streptococcus pneumoniae, and varicella-zoster virus (VZR), which pose serious risks to individuals with chronic respiratory conditions. Evidence supporting the role of vaccines in minimizing exacerbations and improving patient outcomes in asthma, chronic obstructive pulmonary disease, and bronchiectasis is highlighted, alongside recent advancements in vaccine technology and recommendations for high-risk populations. This expert-led, multidisciplinary approach underlines the necessity of targeted immunization strategies to mitigate complications, lower healthcare costs, and enhance the quality of life for patients with respiratory diseases. By collecting the latest evidence-based recommendations, this article aims to guide healthcare providers in adopting optimal vaccination strategies for respiratory disease management and contribute to the broader public health effort to reduce the burden of respiratory infections.</p>","PeriodicalId":21048,"journal":{"name":"Respiration","volume":" ","pages":"1-28"},"PeriodicalIF":3.5,"publicationDate":"2025-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in body water composition and severity of respiratory disease in very preterm infants.","authors":"Alexandra Allanore, Francesco Bonsante, Simon Lorrain, Alexandre Lapillonne, Silvia Iacobelli","doi":"10.1159/000543891","DOIUrl":"https://doi.org/10.1159/000543891","url":null,"abstract":"<p><p>Introduction Acute respiratory disorders and bronchopulmonary dysplasia (BPD) are frequent and serious complications in very preterm infants (VPI). These conditions are influenced by several factors, including fluid imbalances and abnormal postnatal changes in body water composition (BWC). We aimed to investigate the association between BWC and the severity of respiratory disease in VPI using bioelectrical impedance analysis (BIA). Material and Methods We conducted an observational study in a level III NICU at Reunion Island University Hospital. Infants born before 32 weeks of gestation, with BWC monitoring during hospital stay were included. The severity of respiratory disease was assessed using Mean Airway Pressure (MAP) recorded at the same time as BIA. Secondary outcomes included the Lung Ultrasound Score (LUS), measured weekly from 28 days of life, and BDP occurrence and severity at 36 weeks of postconceptional age. Results We included 34 VPI (BW 1131±352g, GA 28.0±2.2) and performed 267 BWC analyses (average: 8 BIA/patient). MAP was directly associated with extracellular water (ECW, % of body weight) (p<0.001), even after adjustment for confounding variables at multivariate analysis (p< 0.02). No significant association was observed between total body water measures and the LUS. ECW was significantly associated with the occurrence of severe BPD (p< 0.003). Conclusion These results highlight the protective effect of the contraction of total body water and in particular of the ECW on the severity of acute and chronic respiratory pathology in VPI. They also indicate the interest of monitoring BWC by BIA throughout hospitalization in critically ill neonates.</p>","PeriodicalId":21048,"journal":{"name":"Respiration","volume":" ","pages":"1-20"},"PeriodicalIF":3.5,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143449822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of airway stent placement in the treatment of airway esophageal fistula.","authors":"Xiangnan Li, Peiyuan Luo, Mengyu Zhao, Feifei Wen, Guancheng Jiang, Yibei You, Yaru Liu, Xuan Wu, Felix J F Herth, Quncheng Zhang","doi":"10.1159/000544124","DOIUrl":"https://doi.org/10.1159/000544124","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to evaluate both the clinical efficacy and safety of airway stent placement in in the treatment of patients with esophageal cancer-associated airway esophageal fistula (AEF). The focus is on evaluating improvements in patient survival and quality of life.</p><p><strong>Methods: </strong>Overall, this study enrolled 111 patients diagnosed with esophageal cancer-associated AEF. Among them, 50 (45.0%) and 61 (55.0%) patients received airway stent placement and conservative treatment, respectively. Follow-up assessments were conducted to determine the clinical efficacy and safety of the interventions, with survival and quality of life as the primary endpoints.</p><p><strong>Results: </strong>By the end of the follow-up, 98 of 111 patients (88.3%) had died, leaving 13 survivors (11.7%). Patients with esophageal cancer-associated AEF had an overall mean survival time of 147.4 (95%CI, 123.9-170.9) days. Patients in the stent placement group had a mean survival of 192.5 (95% CI, 151.2-233.7) days, which was significantly longer than the 110.0 (95% CI, 88.1-131.8) days in the conservative treatment group (p < 0.001). Sex (p = 0.017), tumor stage (p = 0.030), surgery (p = 0.005), pulmonary infection (p < 0.001), fistula size (p < 0.001), and pre-Karnofsky Performance Status (KPS) (p < 0.001) were the independent risk factors affecting survival. Furthermore, patients in the stent placement group demonstrated improved KPS scores post-treatment, increasing from 48.2 to 57.9 (p = 0.017).</p><p><strong>Conclusion: </strong>Airway stent placement is beneficial in alleviating the symptoms, quality of life, and survival of patients with esophageal cancer-associated AEF.</p>","PeriodicalId":21048,"journal":{"name":"Respiration","volume":" ","pages":"1-14"},"PeriodicalIF":3.5,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143442007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pulmonary hypertension in the field of hematological and oncological diseases.","authors":"Mona Lichtblau, Frédéric Lador, Benoit Lechartier, Jana Maria Ellegast, Susanne Pohle, Helga Preiss, Leon Genecand, Carmen Wick, Silvia Ulrich, Lena Reimann","doi":"10.1159/000544126","DOIUrl":"https://doi.org/10.1159/000544126","url":null,"abstract":"<p><p>Hematological and oncological diseases collectively affect a substantial number of patients. Pulmonary hypertension (PH) is recognized as a potential complication associated with these conditions, manifesting in various forms of PH and presenting with a range of symptoms. The complexity of PH in this context arises from its multifactorial etiology, which can include direct effects of malignancies, treatment-related effects and the impact of disease progression. The variability in how PH presents and progresses in patients with hematological diseases and neoplasms complicates its diagnosis and management. Accurate identification of PH alongside the underlying condition is crucial for enabling optimal treatment and improving overall survival. A multidisciplinary approach involving pulmonologists, hematologists, and oncologists is essential to address these challenges effectively. This review aims to summarize recent research findings and enhance the understanding of the complex interactions between PH and hemato-oncological diseases.</p>","PeriodicalId":21048,"journal":{"name":"Respiration","volume":" ","pages":"1-20"},"PeriodicalIF":3.5,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143410326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic Obstructive Pulmonary Disease Burden of Disease from 2017 to 2022: Analysis of 44,260 Hospitalizations in the Italian Apulian Region.","authors":"Emanuela Resta, Giusi Graziano, Giacomo Riformato, Chiara Noviello, Silvio Tafuri, Paola Pierucci","doi":"10.1159/000542908","DOIUrl":"10.1159/000542908","url":null,"abstract":"<p><strong>Introduction: </strong>Natural history of chronic obstructive pulmonary disease (COPD) is characterized by a progressive decline in pulmonary function and recurrent exacerbations, requiring frequent hospital admissions to medical wards. Great heterogeneity still exists between studies hindering our understanding of the true, global burden of AECOPD on healthcare systems over COVID-19 pandemic. We aimed to describe the AECOPD in the southern Italian region from 2017 to 2022 and to detail the location of admission, rate and characteristics of deaths, and use of noninvasive respiratory supports.</p><p><strong>Methods: </strong>Retrospective, cross-sectional study carried out in collaboration with the Apulian Regional Observatory for Epidemiology over the second semester of 2023. Selected records with specific ICD-9 codes related to AECOPD and its clinical details, related complications, number of re-hospitalization, and noninvasive respiratory support use described as \"principal\" or \"secondary\" or \"other diagnosis\" were considered.</p><p><strong>Results: </strong>From 2017 to 2022, a total of 29,917 patients with AECOPD were admitted to hospital, and they generated a total of 44,260 hospitalizations. The male gender represented 60.9% of the total, mean age 77.1 ± 11.2 years. Deaths were 3,743, complicated by other comorbidities in 54% of cases. Readmissions rate was 8.5%. Deaths allocation was as follows: intensive care 37.7%, general medicine 33%, respiratory ward 13.5%, etc. Noninvasive respiratory supports were used in 47% of cases.</p><p><strong>Conclusion: </strong>This prolonged and deeply characterized clinical observation of AECOPD admissions, including COVID-19 pandemic years, in Apulia region, shows that they present at older age, affected by onemore comorbidities with more severe disease requiring in almost half a percentage of cases the use of respiratory support (HFNC and NIV). However, the high rate of deaths highlights the urgent need to further support the most severe cases who deserve more tailored ward allocation and care management.</p>","PeriodicalId":21048,"journal":{"name":"Respiration","volume":" ","pages":"1-10"},"PeriodicalIF":3.5,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143123492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"'Diagnosis and Treatment of Hypersensitivity Pneumonitis' S2k Guideline of the German Respiratory Society and the German Society for Allergology and Clinical Immunology.","authors":"D Koschel, J Behr, M Berger, F Bonella, O Hamer, Marcus Joest, Danny Jonigk, Michael Kreuter, Gabriela Leuschner, Dennis Nowak, Monika Raulf, Beate Rehbock, Jens Schreiber, Helmut Sitter, Dirk Theegarten, Ulrich Costabel","doi":"10.1159/000543675","DOIUrl":"https://doi.org/10.1159/000543675","url":null,"abstract":"<p><p>German recommendations for the diagnosis of hypersensitivity pneumonitis (HP), also known as extrinsic allergic alveolitis (EAA), were last published in 2007 [1]. The current S2k Guideline for the Diagnosis and Treatment of Hypersensitivity Pneumonitis (HP) replaces these diagnostic recommendations. They were supplemented by the aspect of chronic, and in particular of the chronic fibrotic phenotype of HP, and also, as first HP guideline, include treatment recommendations. Based on current scientific evidence and on expert opinion 12 consensus recommendations were developed. They include important statements summarizing the diagnostic process, the treatment indication and therapeutic strategies for patients with HP. Particular emphasis was placed on the different clinical courses (acute and chronic) and their characteristics (inflammatory and/or fibrotic pattern), which present differential diagnostic challenges and ultimately result in different treatment approaches. In addition to general information (diagnosis, classification, clinical disease course, epidemiology, pathogenesis, risk factors, prognosis and special aspects associated with occupational disease), the guideline will present the various clinical disease entities of HP, some in detail, others in tabular form. A major focus is on the various diagnostic steps and the different treatment approaches. The background information serves to provide a deeper understanding and inform the implementation of the recommendations. In particular, other current international guidelines for the diagnosis of HP as well as German guidelines for the diagnosis of Interstitial lung diseases (ILDs) (Leitlinien zur Diagnostik interstitieller Lungenerkrankungen) in general and for the pharmacotherapy of fibrotic ILDs were integrated and considered in this guideline [2-6].</p>","PeriodicalId":21048,"journal":{"name":"Respiration","volume":" ","pages":"1-82"},"PeriodicalIF":3.5,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143053400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Proof of the Pudding Is in the Eating: Real-Life Intra- and Extrapulmonary Impact of Elexacaftor/Tezacaftor/Ivacaftor.","authors":"Stefanie Vincken, Sylvia Verbanck, Sue Braun, Nathalie Buyck, Cindy Zienebergh, Christiane Knoop, Eef Vanderhelst","doi":"10.1159/000543009","DOIUrl":"10.1159/000543009","url":null,"abstract":"<p><strong>Introduction: </strong>Elexacaftor/tezacaftor/ivacaftor (ETI) has shown significant improvements in pulmonary and nutritional status in persons with cystic fibrosis (pwCF). Less is known about the extrapulmonary impact of ETI and effects on airway microbiology, lung clearance index (LCI), and fraction of exhaled nitric oxide (FeNO).</p><p><strong>Methods: </strong>This is a multicenter prospective observational trial, including 79 pwCF ≥18 years eligible for ETI. Assessments were done at the initiation of and 3 and 6 months into treatment with ETI. Outcomes included forced expiratory volume in 1 s (FEV1), LCI, FeNO, sputum or cough swab culture, body mass index (BMI), cystic fibrosis questionnaire-revised respiratory domain (CFQ-R RD), sinonasal outcome test-22 (SNOT-22), general anxiety disorder-7 (GAD-7), patient health questionnaire-9 (PHQ-9), fecal elastase-1 (FE-1), adherence to baseline therapies, exacerbation rate, and adverse events.</p><p><strong>Results: </strong>Our cohort included 79 pwCF (31 ± 11(SD) years) with a baseline ppFEV1 of 68 ± 23. Forty-two (53%) pwCF were previously treated with a CFTR modulator. In the entire study group, there were significant improvements from baseline in ppFEV1, LCI, FeNO, annualized exacerbation rate, BMI, CFQ-R RD, and SNOT-22 (p < 0.05 for all). Airway culture positivity for methicillin-susceptible Staphylococcus aureus and Pseudomonas aeruginosa also decreased during the study period. There was no significant change in FE-1, GAD-7, or PHQ-9. Adherence to dornase alfa and hypertonic saline decreased.</p><p><strong>Conclusion: </strong>ETI treatment led to significant improvements in respiratory and nutritional status, alongside a decrease in adherence to chronic supportive therapies. We did not observe any significant changes in exocrine pancreas function or in questionnaire scores for depression and anxiety.</p>","PeriodicalId":21048,"journal":{"name":"Respiration","volume":" ","pages":"1-9"},"PeriodicalIF":3.5,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bronchiolitis in Adults: Etiology, Diagnostic, and Therapeutic Approach.","authors":"Karolien Viskens, Valerie Van Ballaer, Adriana Dubbeldam, Birgit Weynand, Lieven Dupont","doi":"10.1159/000543226","DOIUrl":"10.1159/000543226","url":null,"abstract":"<p><strong>Background: </strong>Bronchiolitis is a heterogeneous group of disorders, each with its own clinical and radiographic presentation, treatment options, and prognosis. Until now, classifications were based on pathology and radiology.</p><p><strong>Summary: </strong>Bronchioles are smaller than 2 mm in diameter and do not contain cartilage and mucous glands in their walls. Bronchiolitis is the term used to designate a disorder of the bronchioles and can have multiple etiologies. A specific diagnosis requires an extensive anamnesis, physical examination, pulmonary function testing, radiographic studies, and pathological investigation. We made a classification of bronchiolitis based on etiology, in order to give a diagnostic and therapeutic guidance. Further investigation is needed to optimize treatment for specific types of bronchiolitis.</p><p><strong>Key messages: </strong>In this paper, a classification of bronchiolitis based on etiology is made. The paper provides in the diagnostic and therapeutic approach, although further investigation is needed to optimize treatment for specific types of bronchiolitis.</p>","PeriodicalId":21048,"journal":{"name":"Respiration","volume":" ","pages":"1-12"},"PeriodicalIF":3.5,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143010613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding the Growing Burden of Malignant Pleural Effusion - Epidemiology, Healthcare Utilization, and Cost: A Canadian Perspective.","authors":"Kasia Czarnecka-Kujawa, Murray D Krahn, Fangyun Wu, Matthew Stanbrook, George Tomlinson, Kazuhiro Yasufuku, Michael Paterson, Karen E Bremner","doi":"10.1159/000543522","DOIUrl":"10.1159/000543522","url":null,"abstract":"<p><strong>Introduction: </strong>Malignant pleural effusion (MPE) is common in advanced malignancy. Data are needed on healthcare utilization and costs.</p><p><strong>Methods: </strong>This population-based retrospective cohort study included patients aged ≥18 years with an MPE diagnosed between January 1, 2004, and December 31, 2018. We described the incidence and prevalence of MPE from 2004 to 2018 and trends in hospital admissions, emergency department (ED) visits, and pleural-based procedures. In patients diagnosed with MPE from 2006 to 2016, we estimated 2-year healthcare costs (2018 US dollars) from the public payer perspective.</p><p><strong>Results: </strong>The annual incidence and prevalence of MPE increased from 5,090 and 14,579 in 2004 to 6,977 and 23,204 in 2018, respectively. Annual mortality among prevalent patients decreased from 32% to 28%. In 2004, 57% of patients were hospitalized, decreasing to 50% in 2018. ED visits increased (59%-61%). From 2004 to 2018, the number of patients who had insertions of thoracostomy tube (2,211-3,664) and tunneled pleural catheter (383-1,164) increased. The number of patients receiving pleurodesis declined (565-284). No change occurred in the number of patients receiving video-assisted thoracoscopy (range 140-208/year). Between 2004 and 2016, 76,190 patients were diagnosed with MPE (mean age 71.2; 52% female). The median (interquartile range) healthcare cost during follow-up was USD 45,641 (USD 23,237-USD 86,700), with USD 19,753 (USD 9,590-USD 38,746) for inpatient hospitalization.</p><p><strong>Conclusion: </strong>Hospitalization and temporizing MPE procedures are associated with high costs. This population-based study may guide clinicians and policymakers to improve MPE management and reduce healthcare costs.</p>","PeriodicalId":21048,"journal":{"name":"Respiration","volume":" ","pages":"1-13"},"PeriodicalIF":3.5,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143010615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}